| Total | SF6 | C2F6 | C3F8 | Densiron | SO 1000cs | SO 5000 cs | p Value |
---|---|---|---|---|---|---|---|---|
Total | 1012 | 341 | 338 | 239 | 33 | 43 | 18 | – |
Age (years, IQR) | 59 (53 to 68) | 59 (53 to 67) | 61 (54 to 67) | 59 (52 to 66) | 61 (55 to 74) | 63 (54 to 71) | 55 (37 to 63) | 0.087 |
Gender (% Male) | 648 (64.0%) | 215 (63.0%) | 204 (60.4%) | 158 (66.1%) | 26 (78.8%) | 29 (67.4%) | 16 (88.9%) | 0.057 |
Laterality (% Right) | 528 (52.2%) | 172 (50.4%) | 195 (57.7%) | 113 (47.3%) | 17 (51.5%) | 21 (48.8%) | 10 (55.6%) | 0.213 |
High Myope (% Yes) | 61 (6.0%) | 20 (5.9%) | 25 (7.4%) | 10 (4.2%) | 3 (9.1%) | 2 (4.7%) | 1 (5.6%) | 0.659 |
Ocular Co-morbidities | 212 (20.9%) | 50 (14.7%) | 73 (21.6%) | 49 (20.5%) | 18 (54.5%) | 14 (32.6%) | 8 (44.4%) | < 0.001 |
Preoperative Lens |  |  |  |  |  |  |  | – |
Phakic | 644 (69.0%) | 241 (75.5%) | 220 (69.0%) | 138 (63.6%) | 18 (60.0%) | 17 (53.1%) | 10 (62.5%) | 0.012 |
Pseudophakic | 289 (31.0%) | 78 (24.5%) | 99 (31.0%) | 79 (36.4%) | 12 (40.0%) | 15 (46.9%) | 6 (37.5%) | |
Macula Status | Â | Â | Â | Â | Â | Â | Â | Â |
Off | 497 (49.1%) | 116 (34.0%) | 192 (56.8%) | 122 (51.0%) | 23 (69.7%) | 32 (74.4%) | 12 (66.7%) | < 0.001 |
On | 515 (50.9%) | 225 (66.0%) | 146 (43.2%) | 117 (49.0%) | 10 (30.3%) | 11 (25.6%) | 6 (33.3%) | |
Giant Retinal Tear | 7 (0.7%) | 0 (0.0%) | 1 (0.3%) | 0 (0.0%) | 0 (0.0%) | 3 (7.0%) | 3 (16.7%) | < 0.001 |
PVR C | 16 (1.6%) | 0 (0.0%) | 0 (0.0%) | 3 (1.3%) | 3 (9.1%) | 8 (18.6%) | 2 (11.1%) | < 0.001 |
Retinectomy | 3 (0.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 3 (7.0%) | 0 (0.0%) | < 0.001 |
Perfluorocarbon | 36 (3.6%) | 5 (1.5%) | 5 (1.5%) | 6 (2.5%) | 3 (9.1%) | 10 (23.3%) | 7 (38.9%) | < 0.001 |
Combined Buckle/PPV | 13 (1.3%) | 1 (0.3%) | 1 (0.3%) | 6 (2.5%) | 0 (0.0%) | 4 (9.3%) | 1 (5.6%) | < 0.001 |
Presentation to Surgery (days) | 1 (0 to 4) | 1 (0 to 1) | 1 (0 to 4) | 1 (0 to 5) | 2 (0 to 7) | 2 (0 to 7) | 2 (0 to 7) | < 0.001 |
Postoperative Lens |  |  |  |  |  |  |  | – |
Phakic | 471 (46.5%) | 187 (54.8%) | 168 (49.7%) | 107 (44.8%) | 3 (9.1%) | 3 (7.0%) | 3 (16.7%) | < 0.001 |
Pseudophakic | 541 (53.5%) | 154 (45.2%) | 170 (50.3%) | 132 (55.2%) | 30 (90.9%) | 40 (93.0%) | 15 (83.3%) | |
Duration of oil (days) | 147 (91 to 215) | – | – | – | 84 (68 to 124) | 171 (125 to 222) | 202 (162 to 308) | < 0.001 |
Visual Loss | 57 (5.6%) | 13 (3.8%) | 14 (4.1%) | 15 (6.3%) | 2 (6.1%) | 9 (20.9%) | 4 (22.2%) | < 0.001 |
Unexplained Visual Loss | 15 (1.5%) | 1 (0.3%) | 4 (1.2%) | 2 (0.8%) | 0 (0.0%) | 5 (11.6%) | 3 (16.7%) | < 0.001 |